Highest-materiality recent filing
Caribou Q1 2026 rev flat at $2.4M; FDA aligns on pivotal trial for vispa-cel
FDA alignment on ANTLER-3 pivotal phase 3 trial for vispa-cel in 2L LBCL; primary endpoint PFS, crossover allowed.
Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma
FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.
Caribou Biosciences FY2025 net loss $148.1M; cash $142.8M funds into 2H 2027
GAAP net loss FY2025 $148.1M ($1.59/sh) vs $149.1M ($1.65) prior year; non-GAAP loss $126.8M excluding $21.3M impairment.
Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M
Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).
Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M
Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.
Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025
GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.
Caribou Biosciences regains Nasdaq minimum bid price compliance after 10-day period above $1.00
Received Nasdaq compliance notice on June 18, 2025, confirming regained compliance with Listing Rule 5450(a)(1).
Caribou Biosciences stockholders approve reverse stock split authorization at annual meeting
Class I directors elected: Scott Braunstein (40.2M votes for) and Ran Zheng (30.4M votes for).
Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027
Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).
Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027
Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring
Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.
Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO
Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.
Caribou Biosciences appoints Sri Ryali as CFO, effective January 2, 2025
Sri Ryali named CFO; brings 20 years biopharma finance experience; most recently CFO of Codexis.
Caribou Q3 net loss $34.7M vs $10.0M YoY; cash $281M funds into H2 2026
Revenue $2.0M, down from $23.7M due to AbbVie termination; R&D expense $30.4M.
Caribou Biosciences appoints Ryan Fischesser interim CFO and grants 25,000 RSUs
Ryan Fischesser designated interim principal financial officer and accounting officer effective Sept 27, 2024, following Jason O'Byrne's resignation.
CFO Jason O'Byrne resigns effective Sept 27; Ryan Fischesser named principal accounting officer
Jason O'Byrne resigns as CFO effective Sept 27, 2024, to pursue other opportunity; no disagreement with company.
Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer
Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.
Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut
Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.
Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026
Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
Caribou Biosciences stockholders elect three directors and ratify auditor at 2024 annual meeting
Elected Class III directors: Rachel Haurwitz (57.4M for), Dara Richardson-Heron (50.2M for), Natalie Sacks (50.2M for).
Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching
Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).
Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus
Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.
FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.
Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates
Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.
On January 2, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), announced the appointment of Sriram Ryali, age 44, to the position of Chief Financial Officer (“CFO”) of the Company, effective as of January 2, 2025 (the “Start Date”).
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of 5:00 p.m. Pacific time on September 27, 2024.
Mr. O’Byrne serves as the Company’s principal financial officer and principal accounting officer through September 27, 2024, his final day with the Company.
On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.
The Company intends to appoint Ryan Fischesser, the Company’s current Vice President of Finance and Controller, to assume the role of the Company’s principal accounting officer, effective as of the close of business on September 27, 2024.
Max materiality 0.85 · Median 0.65 · Most common event earnings